Position in NVS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$227,870
New position
Shares Held
1,454
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,259
of 1,603 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 202671 West Capital Partners holds $21,155,532 across 11 Drug Manufacturers - General names. NVS ranks #10 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
5,922 | $7,103,025 | |
| 2 | JNJ |
Johnson & Johnson
|
15,732 | $3,995,456 | |
| 3 | ABBV |
AbbVie Inc.
|
12,555 | $3,159,340 | |
| 4 | MRK |
Merck & Co., Inc.
|
16,058 | $2,063,453 | |
| 5 | AMGN |
Amgen Inc
|
3,626 | $1,313,047 | |
| 6 | AZN |
Astrazeneca PLC
|
5,676 | $1,076,283 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
16,821 | $969,226 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
6,321 | $798,595 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $227,870 | 1,454 | Shares | Sole | 2026-08-04 | |
| No filing history on record for this holder in this stock. | ||||||